Asset profile
Ciclesonide (XRP1526)
Small molecule
Evidence outlook
No registered development activity since 2009
Registered studies concluded by 2009, with no approval on record and no active or planned study on the registry since. No sponsor statement of discontinuation has been sourced, but the trial history should be read as archival rather than an active program.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
80 competitors in this universe: 9 direct rivals (same mechanism and indication), 11 same-class, 60 same-indication; 48 further along in development.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Ciclesonide (XRP1526): this drug | Phase 3 | Small molecule | Glucocorticoid receptor | ||
| Albuterol / Budesonide (Airsupra) | Approved | Combination | Beta-2 adrenergic receptor, Glucocorticoid receptor, Glucocorticoid receptor / Beta-2 adrenergic receptor | ||
| Beclomethasone (QVAR) | Approved | Small molecule | Glucocorticoid receptor | ||
| Ciclesonide (Alvesco) | Approved | Small molecule | Glucocorticoid receptor | ||
| Fluticasone Furoate | Approved | Small molecule | Glucocorticoid receptor | ||
| Fluticasone Furoate / Umeclidinium / Vilanterol (Trelegy Ellipta) | Approved | Small molecule | Muscarinic acetylcholine receptor (M3), Beta-2 adrenergic receptor, Glucocorticoid receptor, Glucocorticoid receptor / Beta-2 adrenergic receptor / Muscarinic M3 receptor (ICS/LABA/LAMA triple combination) | ||
| Fluticasone Furoate / Vilanterol | Approved | Small molecule | Beta-2 adrenergic receptor, Glucocorticoid receptor, Glucocorticoid receptor / Beta-2 adrenergic receptor | ||
| Fluticasone Propionate | Approved | Small molecule | Glucocorticoid receptor | ||
| Fluticasone Propionate / Salmeterol (Advair HFA) | Approved | Combination | Glucocorticoid receptor, Beta-2 adrenergic receptor, Glucocorticoid receptor / Beta-2 adrenergic receptor | ||
| Lodotra (Rayos) | Approved | — | Glucocorticoid receptor | ||
| Budesonide (Entocort EC) | Approved | — | Glucocorticoid receptor | ||
| Budesonide (Ortikos) | Approved | — | Glucocorticoid receptor | ||
| Budesonide (targeted-Release) (TARPEYO / Nefecon) | Approved | Small molecule | Glucocorticoid receptor | ||
| Budesonide (Uceris Rectal Foam) | Approved | — | Glucocorticoid receptor | ||
| Budesonide MMX (Uceris) | Approved | — | Glucocorticoid receptor | ||
| Halobetasol Propionate Foam (Lexette) | Approved | Small molecule | Glucocorticoid receptor |
…and 65 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Compare head-to-head
3 further head-to-head pairs are tracked; the rosters on each shared mechanism and indication page list every rival in the race.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.